Alexander P. J. Vlaar, Endry H. T. Lim, Sanne deBruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, . . . Diederik van deBeek. (2022). The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19. Wiley.
Chicago Style (17th ed.) CitationAlexander P. J. Vlaar, et al. The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19. Wiley, 2022.
MLA (9th ed.) CitationAlexander P. J. Vlaar, et al. The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19. Wiley, 2022.
Warning: These citations may not always be 100% accurate.